ursodeoxycholic acid has been researched along with Disease Models, Animal in 107 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 1 (0.93) | 18.7374 |
1990's | 4 (3.74) | 18.2507 |
2000's | 25 (23.36) | 29.6817 |
2010's | 57 (53.27) | 24.3611 |
2020's | 20 (18.69) | 2.80 |
Authors | Studies |
---|---|
Carino, A; Cipriani, S; D'Amore, C; De Marino, S; Festa, C; Finamore, C; Fiorucci, S; Monti, MC; Renga, B; Sepe, V; Zampella, A | 1 |
Pan, JC; Tu, LL; Yin, LN; Zhang, Y; Zhang, YW; Zheng, GL | 1 |
Hirayama, T; Honda, A; Ikegami, T; Iwamoto, J; Miyazaki, T; Morishita, Y; Nakamoto, N; Ueda, H | 1 |
Fujitsuka, N; Iizuka, S; Ishizawa, S; Kaifuchi, N; Kono, T; Nahata, M; Nishi, A; Nishiyama, M; Ohbuchi, K; Shimobori, C; Yamada, C; Yamamoto, M | 1 |
Li, W; Liu, X; Liuqi, S; Peng, B; Wang, J; Wang, S; Yin, J; Zhang, B; Zhang, Y | 1 |
Bai, Y; Han, D; Jia, W; Li, D; Lian, S; Lu, D; Ni, D; Pi, Y; Tao, S; Wang, J; Wang, Z; Wu, Y; Ye, H; Zhang, G; Zhang, S; Zhang, X; Zhao, J; Zheng, X; Zou, X | 1 |
Chu, FH; Dai, ZQ; Gao, F; Gao, S; Jiang, XQ; Kong, JW; Lei, HM; Li, SL; Lu, MJ; Wang, ZJ; Xu, B; Xu, SJ; Zheng, HC | 1 |
Jiang, HX; Liang, ZY; Qin, SY; Su, SB; Wang, F; Yan, YD; Zhangdi, HJ | 1 |
Feng, W; Hao, Z; Liu, Y; Ren, L; Song, Q; Zhang, L | 1 |
Nakanuma, Y; Sasaki, M; Sato, Y | 1 |
Chen, L; Chen, XZ; Wu, PB; Ye, HL; Zhang, G; Zhang, JW | 1 |
Arai, T; Araki, F; Fukunaga, H; Kato, S; Moriya, K; Shiraya, T; Totsuka, K; Uemura, A; Ueta, T | 1 |
Banales, JM; Briz, O; Bujanda, L; Caballero-Camino, FJ; Cossío, FP; Esteller, M; Gradilone, SA; Herraez, E; Izquierdo-Sanchez, L; Jin, S; Lee-Law, PY; Marin, JJG; Munoz-Garrido, P; Peixoto, E; Perugorria, MJ; Richard, S; Rivilla, I; Rodrigues, PM; Santos-Laso, A | 1 |
Huang, R; Huang, Y; Jin, Y; Li, M; Zeng, G | 1 |
Bian, Z; Ge, K; Han, X; Huang, F; Jia, W; Li, M; Qu, C; Rajani, C; Wang, S; Wei, M; Xie, G; Yang, W; Zhang, Y; Zhao, A; Zhao, L; Zheng, X | 1 |
Curley, C; Fallon, CM; Keely, SJ; Lajczak-McGinley, NK; McCarron, PA; Porru, E; Roda, A; Smyth, J; Tambuwala, MM | 1 |
Al-Salami, H; Goločorbin-Kon, S; Ionescu, CM; Kojic, S; Kovacevic, B; Luna, G; Mikov, M; Mooranian, A; Stojanovic, G; Zamani, N | 1 |
Cui, Y; Fan, N; Gao, Q; Hu, Y; Li, D; Li, Y; Meng, K; Wang, J; Wu, S; Zhang, Y | 1 |
Fort-Aznar, L; Sweeney, ST; Ugbode, C; West, RJH | 1 |
Gül, A; Sönmezgöz, E; Takci, S; Uysal, M | 1 |
Dong, X; Lu, S; Luo, Y; Ma, H; Sun, G; Sun, X; Zhang, W; Zhu, Y | 1 |
Chang, G; Chen, S; Guo, Z; Huang, K; Li, Z; Liu, C; Liu, R; Peng, M; Su, Q | 1 |
Alteneder, M; Baazim, H; Bergthaler, A; Boucheron, N; Claudel, T; Donner, C; Ellmeier, W; Fuchs, CD; Gülich, AF; Hainberger, D; Halilbasic, E; Hamminger, P; Khan, M; Lercher, A; Májek, P; Müller, AC; Ohradanova-Repic, A; Preglej, T; Remetic, J; Sakaguchi, S; Sandner, L; Scharnagl, H; Schatzlmaier, P; Stockinger, H; Stojakovic, T; Trauner, M; Viczenczova, C; Weichhart, T; Zhu, C | 1 |
Bowlus, C; Floreani, A; Gershwin, ME; Tanaka, A | 1 |
Costelha, S; Martins, HS; Saraiva, MJ; Teixeira, A; Teixeira, C | 1 |
Erbas, M; Erdem, H; Kiraz, HA; Ku Çu K, A; Özkan, A; Tekin, M; Topaloglu, N; Yildirim, S | 1 |
Cho, ML; Choi, JY; Jung, KA; Kim, DS; Kim, EK; Kwon, JE; Lee, EJ; Lee, SH; Park, MJ; Park, SH | 1 |
Fickert, P; Krones, E; Pollheimer, MJ; Rosenkranz, AR | 1 |
Alaca, N; Çağlayan Yeğen, B; Kurtel, H; Öktem, G; Özbeyli, D; Şahin, HH; Uslu, S; Yiğittürk, G | 1 |
Escobar, OH; Frey, MR; Gayer, CP; Golden, JM; Kavarian, P; Mallicote, MU; Nguyen, MVL | 1 |
Campeau, J; Norman, G; Sim, VL | 1 |
Abdel-Ghaffar, A; Ahmed, EK; Ghanem, HM; Hassanin, OA; Mohamed, RG | 1 |
Dehghanian, A; Dorvash, MR; Firouzabadi, N; Khoshnood, MJ; Mosaddeghi, P; Saber, H | 1 |
Blomenkamp, KS; Fickert, P; Tang, Y; Teckman, JH; Trauner, M | 1 |
Chen, CY; Lin, NC; Liu, C; Liu, CP; Tsai, HL; Yeh, YC; Yeh, YT | 1 |
Azarbayjani, AF; Gheibi, S; Gouvarchin Ghaleh, HE; Motlagh, BM; Zarei, L | 1 |
Andermatten, RB; Barosso, IR; Basiglio, CL; Ciriaci, N; Maidagan, PM; Martín, PL; Razori, MV; Roma, MG; Ruiz, ML; Sánchez Pozzi, EJ | 1 |
Cheng, D; Dong, JH; Guo, YJ; Jin, F; Pang, R; Tao, JY; Ye, P; Zhang, SL; Zhao, L | 1 |
Forrest, D; Hagey, LR; Hofmann, AF; Ling, V; Liu, L; Sheps, JA; Wang, R | 1 |
Denk, H; Eggertsen, G; Eller, K; Fickert, P; Halilbasic, E; Jaeschke, H; Krones, E; Langner, C; Moustafa, T; Pollheimer, MJ; Rosenkranz, AR; Silbert, D; Stokman, G; Thueringer, A; Trauner, M; Wagner, CA; Wells, RG; Yang, M | 1 |
Boyer, JL; Cai, SY; Mennone, A; Soroka, CJ | 1 |
Barbosa, M; Brites, D; Cunha, C; Gomes, C; Schmucki, N; Vaz, AR | 1 |
Fujimura, T; Fushida, S; Harada, S; Hattori, T; Kinoshita, J; Miyashita, T; Mukaisho, K; Ohta, T; Ojima, E; Oyama, K; Tajima, H; Tsukada, T | 1 |
Claudel, T; Engelmann, R; Fickert, P; Fuchs, CD; Guenther, ND; Langner, C; Loebermann, M; Mueller, M; Mueller-Hilke, B; Österreicher, CH; Reisinger, EC; Sahin, E; Schramm, C; Schwinge, D; Sombetzki, M; Trauner, M | 1 |
Chen, H; Ding, R; Lin, T; Luo, Q; Sun, C; Wang, G; Xu, Y; Zeng, D; Zeng, Z; Zhang, XK | 1 |
Abdelkader, NF; Safar, MM; Salem, HA | 1 |
Banales, JM; Beuers, U; Bujanda, L; Concepcion, AR; Drenth, JP; Erice, O; Hijona, E; Jimenez-Agüero, R; LaRusso, NF; Marin, JJ; Marzioni, M; Masyuk, TV; Monte, MJ; Munoz-Garrido, P; Perugorria, MJ; Portu, A; Prieto, J; Romero, MR; Sáez, E; Santos-Laso, Á; Sarvide, S; Úriz, M; Urribarri, AD | 1 |
Chamulitrat, W; Liebisch, G; Okun, JG; Pathil, A; Schmitz, G; Stremmel, W | 1 |
Abdel-Latif, HA; Ali, MH; Messiha, BA | 1 |
Carlson, CG; Lavin, J; Luo, K; Nielsen, C; Potter, R; Yu, V | 1 |
An, SH; Chung, J; Kim, KH; Kwon, K; Lee, SC | 1 |
Dokuyucu, R; Dolapcioglu, K; Gozukara, I; Kucur, SK; Kurt, RK; Özcan, O; Özgür, T; Pınar, N | 1 |
Halilbasic, E; Kuntner, C; Langer, O; Mairinger, S; Müller, M; Römermann, K; Stieger, B; Trauner, M; Visentin, M; Wanek, T | 1 |
He, X; Li, Z; Liu, W; Liu, X; Liu, Y; Wang, B; Wang, T; Zeng, H | 1 |
Blomenkamp, K; Fickert, P; Marcus, N; Tang, Y; Teckman, J; Trauner, M | 1 |
Al-Salami, H; Elahy, M; Lam, V; Mamo, JC; Mooranian, A; Negrulj, R; Takechi, R | 1 |
De Vos, M; Devisscher, L; Devriese, S; Hindryckx, P; Holvoet, T; Laukens, D; Pieper, DH; Van de Wiele, T; Van den Bossche, L; Van Welden, S; Vanden Bussche, J; Vanhaecke, L; Vilchez-Vargas, R; Vital, M | 1 |
Eller, K; Fickert, P; Frauscher, B; Grahammer, F; Huber, TB; Kirsch, AH; Krones, E; Marschall, HU; Pollheimer, MJ; Racedo, S; Rosenkranz, AR; Ståhlman, M; Trauner, M; Wagner, K; Wahlström, A | 1 |
Halilbasic, E; Steinacher, D; Trauner, M | 1 |
Fickert, P; Halilbasic, E; Moustafa, T; Trauner, M | 1 |
Cuperus, FJ; Hafkamp, AM; Havinga, R; Ostrow, JD; Tiribelli, C; Verkade, HJ; Vitek, L; Zelenka, J | 1 |
Berge, J; Bledsoe, C; Carlson, CG; Gatti, F; Lavin, J; Millman, G; Palmeiri, B; Rutter, J; Siegel, AL; Turin, E; Winders, WT | 1 |
Beuers, U; Rust, C | 1 |
Kim, JH; Woo, SJ; Yu, HG | 1 |
Almada, LL; Buttar, NS; Comba, A; Demars, CJ; Fernández-Zapico, ME; Gainullin, VG; Lomberk, G; Rizvi, S; Rizvi, Z; Wang, K | 1 |
Abdollahi, M; Baeeri, M; Esmaily, H; Miroliaee, AE; Vaziri-Bami, A | 1 |
Angelopoulou, K; Flaskos, J; Karkavelas, G; Kouti, V; Papazoglou, L; Rallis, T | 1 |
Boyer, JL; Cai, SY; He, H; Mennone, A | 1 |
Fabris, L; Fiorotto, R; Hoque, R; Scirpo, R; Spirli, C; Strazzabosco, M; Trauner, M | 1 |
Gorelik, J; Hague, WM; Kadir, SH; Lab, MJ; Miragoli, M; Moshkov, A; Nikolaev, VO; Rohr, S; Salvarani, N; Sheppard, MN; Virta, M; Wells, S; Williamson, C | 1 |
Fauler, G; Fickert, P; Frank, S; Guelly, C; Gumhold, J; Höfler, G; Kratky, D; Lass, A; Magnes, C; Moustafa, T; Reicher, H; Sattler, W; Silbert, D; Sinner, F; Thueringer, A; Trauner, M; Zechner, R | 1 |
Chamulitrat, W; Mueller, J; Pathil, A; Stremmel, W; Warth, A | 1 |
Jelic, M; Jevtovic-Stoimenov, T; Kocic, G; Nikolic, J; Sokolovic, D; Sokolovic, DM; Stanojkovic, Z; Stojanovic, M; Veljkovic, A | 1 |
Chen, Y; Forman, BM; Henkin, A; Her, C; Kazantzis, M; Lai, R; Lin, M; Maher, JJ; Ng, S; Nie, B; Park, HM; Song, S; Stahl, A; Tran, H | 1 |
Chang, MH; Chen, HL; Chen, YH; Chien, CS; Chou, SP; Ling, V; Wang, R; Wu, SH; Yuan, RH | 1 |
Chandok, N; Hirschfield, GM | 1 |
Grefhorst, A; Hammad, H; Hoogsteden, HC; Kleinjan, A; Lambrecht, BN; Moons, L; van Nimwegen, M; Willart, MA | 1 |
Aranda, CJ; de Medina, FS; González, R; Hernández-Chirlaque, C; Marín, JJ; Martínez-Augustin, O; Martínez-Moya, P; Requena, P; Romero-Calvo, I; Suárez, MD; Zarzuelo, A | 1 |
Choi, MK; Han, JM; Hwang, SY; Kim, HG; Lee, JS; Park, HJ; Son, CG; Son, SW; Wang, JH | 1 |
Shi, TY; Zhang, FC | 1 |
Denk, H; Fickert, P; Fuchsbichler, A; Lammert, F; Marschall, HU; Stumptner, C; Trauner, M; Tsybrovskyy, O; Weiglein, AH; Zatloukal, K; Zollner, G | 1 |
Bissonnette, M; Brasitus, T; Hart, J; Nguyen, L; Sitrin, MD; Stoiber, D; Wali, RK | 1 |
Bissonnette, M; Brasitus, T; Cohen, G; Hart, J; Joseph, L; Khare, S; Nguyen, L; Ramaswamy, A; Sitrin, M; Tretiakova, M; Wali, RK; Wang, J; Wen, M | 1 |
Briz, O; Macias, RI; Marin, JJ; Serrano, MA; Silva, A; Vallejo, M | 1 |
Barone, M; Berloco, P; Caruso, ML; Di Leo, A; Francavilla, A; Ierardi, E; Ladisa, R; Maiorano, E; Pece, A; Strazzabosco, M; Valentini, AM | 1 |
Agostinho, CL; Bernardes-Silva, CF; Buchpiguel, CA; Damião, AO; Iriya, K; Laudanna, AA; Laurindo, FR; Lopasso, FP; Lordello, ML; Sipahi, AM | 1 |
Duran, C; Gonzalez-Buitrago, JM; Macias, RI; Marin, JJ; Monte, MJ; Perez, MJ | 1 |
Cao, M; Hanski, C; Hanski, ML; Jahreis, G; Keller, S; Loddenkemper, C; Stein, H; Zeitz, M | 1 |
Alpini, G; Benedetti, A; Fava, G; Francis, H; Glaser, S; Mancino, MG; Marzioni, M; Reichenbach, R; Summers, R; Ueno, Y; Venter, J | 1 |
Cover, C; Denk, H; Fickert, P; Fuchsbichler, A; Hofmann, AF; Jaeschke, H; Liu, J; Marschall, HU; Trauner, M; Tsybrovskyy, O; Waalkes, MP; Wagner, M; Zatloukal, K; Zollner, G | 1 |
Abitbol, M; Deybach, JC; Guénet, JL; Montagutelli, X; Puy, H; Sabaté, JM | 1 |
Buko, V; Knas, M; Lukivskaya, O; Zavodnik, L | 1 |
Kohno, H; Miyamoto, S; Suzuki, R; Tanaka, T; Wakabayashi, K; Yasui, Y | 1 |
Pérez-Holanda, S; Piñol Felis, C; Rodrigo, L; Viñas Salas, J | 1 |
Moseley, RH | 1 |
Michael, S; Simko, V | 1 |
Bundy, M; Schwarzenberg, SJ | 1 |
Beno, DW; Jiyamapa-Serna, VA; Kimura, RE; Lloyd-Still, JD; Uhing, MR | 1 |
Criado, JM; de La Fuente, A; Dominguez, MF; Izco-Basurko, I; Macias, RI; Marin, JJ; Monte, MJ; Pascual, MJ; Yajeya, J | 1 |
Lagoo, A; McMurray, RW; Suwannaroj, S | 1 |
Aki, H; Goto, M; Okamoto, Y; Yamamoto, M | 1 |
Houchi, H; Momen, MA; Monden, Y; Umemoto, A | 1 |
Ivanova, NL; Sadovnikova, IV; Sadovnikova, VV | 1 |
Fan, J; Li, M; Tian, L; Wang, G; Wu, W; Zhong, L | 1 |
Clerici, C; Distrutti, E; Dozzini, G; Gentili, G; Natalini, B; Pelli, MA; Pellicciari, R; Rizzoli, R; Roda, A; Sadeghpour, BM | 1 |
Ceryak, S; Fromm, H; Malavolti, M; Shehan, KL | 1 |
Cohen, BI; Kuroki, S; McSherry, CK; Mosbach, EH | 1 |
7 review(s) available for ursodeoxycholic acid and Disease Models, Animal
Article | Year |
---|---|
Crosstalk network among multiple inflammatory mediators in liver fibrosis.
Topics: Animals; Bridged Bicyclo Compounds, Heterocyclic; Disease Models, Animal; Hepatic Stellate Cells; Hepatocytes; Humans; Imidazoles; Inflammation; Inflammation Mediators; Liver; Liver Cirrhosis; Molecular Targeted Therapy; Protein Kinase Inhibitors; Pyrimidinones; Signal Transduction; Sulfoxides; Ursodeoxycholic Acid | 2019 |
Geoepidemiology and changing mortality in primary biliary cholangitis.
Topics: Animals; Chenodeoxycholic Acid; Cholagogues and Choleretics; Disease Models, Animal; Drug Design; Fluorescent Antibody Technique, Indirect; Humans; Liver Cirrhosis, Biliary; Precision Medicine; Ursodeoxycholic Acid | 2017 |
Cholemic nephropathy - Historical notes and novel perspectives.
Topics: Acute Kidney Injury; Animals; Bile Acids and Salts; Bile Ducts; Bilirubin; Cholagogues and Choleretics; Cholestasis; Disease Models, Animal; Epithelial Cells; Hepatocytes; Humans; Jaundice, Obstructive; Kidney Tubules; Liver; Renal Elimination; Ursodeoxycholic Acid | 2018 |
Nor-Ursodeoxycholic Acid as a Novel Therapeutic Approach for Cholestatic and Metabolic Liver Diseases.
Topics: Animals; Cholestasis; Disease Models, Animal; Drug Evaluation, Preclinical; Humans; Liver Diseases; Metabolic Diseases; Ursodeoxycholic Acid | 2017 |
Lessons from the toxic bile concept for the pathogenesis and treatment of cholestatic liver diseases.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP-Binding Cassette Sub-Family B Member 4; Bile; Bile Acids and Salts; Bile Canaliculi; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Carcinoma, Hepatocellular; Cell Transformation, Neoplastic; Cholangiocarcinoma; Cholangitis, Sclerosing; Cholestasis, Intrahepatic; Cholic Acids; Disease Models, Animal; Humans; Liver Neoplasms; Mice; Mice, Knockout; Mutation; Norsteroids; Ursodeoxycholic Acid | 2008 |
Management of primary sclerosing cholangitis: conventions and controversies.
Topics: Animals; Chemokines; Cholagogues and Choleretics; Cholangiography; Cholangiopancreatography, Magnetic Resonance; Cholangitis, Sclerosing; Disease Models, Animal; Genome-Wide Association Study; Humans; Liver Transplantation; Magnetic Resonance Imaging; Ursodeoxycholic Acid | 2012 |
Role of autoimmunity in primary biliary cirrhosis.
Topics: Animals; Autoantibodies; Autoimmunity; B-Lymphocytes; CD4-Positive T-Lymphocytes; Chemokines; Disease Models, Animal; Female; Humans; Immunity, Cellular; Immunity, Humoral; Immunity, Innate; Immunoglobulin M; Interleukin-2 Receptor alpha Subunit; Killer Cells, Natural; Liver Cirrhosis, Biliary; Mice; Ursodeoxycholic Acid | 2012 |
100 other study(ies) available for ursodeoxycholic acid and Disease Models, Animal
Article | Year |
---|---|
Exploitation of cholane scaffold for the discovery of potent and selective farnesoid X receptor (FXR) and G-protein coupled bile acid receptor 1 (GP-BAR1) ligands.
Topics: Animals; Bile Acids and Salts; Chemistry Techniques, Synthetic; Cholanes; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; HEK293 Cells; Hep G2 Cells; Humans; Ligands; Male; Mice, Inbred C57BL; Mice, Mutant Strains; Molecular Targeted Therapy; Pruritus; Receptors, Cytoplasmic and Nuclear; Receptors, G-Protein-Coupled; Small Molecule Libraries; Structure-Activity Relationship | 2014 |
Liver-targeted delivery of asiatic acid nanostructured lipid carrier for the treatment of liver fibrosis.
Topics: Animals; Carbon Tetrachloride; Cell Line; Cell Proliferation; Chemistry, Pharmaceutical; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Carriers; Drug Liberation; Lipids; Liver; Liver Cirrhosis; Liver Function Tests; Male; Mice; Mice, Inbred ICR; Nanostructures; Particle Size; Pentacyclic Triterpenes; Polyethylene Glycols; Rats; Rats, Sprague-Dawley; Surface Properties; Ursodeoxycholic Acid | 2021 |
Sex-, age-, and organ-dependent improvement of bile acid hydrophobicity by ursodeoxycholic acid treatment: A study using a mouse model with human-like bile acid composition.
Topics: Animals; Bile Acids and Salts; Disease Models, Animal; Female; Humans; Hydrophobic and Hydrophilic Interactions; Infant, Newborn; Liver; Male; Premature Birth; Ursodeoxycholic Acid | 2022 |
Integrated analysis of effect of daisaikoto, a traditional Japanese medicine, on the metabolome and gut microbiome in a mouse model of nonalcoholic fatty liver disease.
Topics: Amino Acids; Animals; Arachidonic Acids; Diet, High-Fat; Disease Models, Animal; Drugs, Chinese Herbal; Gastrointestinal Microbiome; Japan; Lipids; Liver; Medicine, Traditional; Metabolome; Mice; Mice, Inbred C57BL; Non-alcoholic Fatty Liver Disease; Ursodeoxycholic Acid | 2022 |
Fucoidan Ameliorated Dextran Sulfate Sodium-Induced Ulcerative Colitis by Modulating Gut Microbiota and Bile Acid Metabolism.
Topics: Animals; Colitis; Colitis, Ulcerative; Colon; Dextran Sulfate; Disease Models, Animal; Gastrointestinal Microbiome; Inflammation; Mice; Mice, Inbred C57BL; Ursodeoxycholic Acid | 2022 |
Gut microbiota-derived ursodeoxycholic acid alleviates low birth weight-induced colonic inflammation by enhancing M2 macrophage polarization.
Topics: Animals; Birth Weight; Colitis; Disease Models, Animal; Dysbiosis; Gastrointestinal Microbiome; Inflammation; Mice; Swine; Ursodeoxycholic Acid | 2023 |
[Therapeutic effect of ursodeoxycholic acid-berberine supramolecular nanoparticles on ulcerative colitis based on supramolecular system induced by weak bond].
Topics: Animals; Berberine; Colitis; Colitis, Ulcerative; Colon; Dextran Sulfate; Disease Models, Animal; Drugs, Chinese Herbal; Interleukin-6; Mice; Nanoparticles; Tumor Necrosis Factor-alpha; Ursodeoxycholic Acid | 2023 |
Probiotic Lactobacillus rhamnosus GG prevents progesterone metabolite epiallaopregnanolone sulfate-induced hepatic bile acid accumulation and liver injury.
Topics: Angiogenic Proteins; Animals; Bile Acids and Salts; Bilirubin; Chenodeoxycholic Acid; Cholestasis; Cholesterol 7-alpha-Hydroxylase; Cholic Acid; Cytokines; Disease Models, Animal; Gastrointestinal Microbiome; Inflammation; Lacticaseibacillus rhamnosus; Liver; Male; Mice; Mice, Inbred C57BL; Pregnanolone; Probiotics; RNA-Binding Proteins; Signal Transduction; Ursodeoxycholic Acid | 2019 |
Increased p16
Topics: Animals; bcl-X Protein; Bile Ducts; Biomarkers; Case-Control Studies; Cellular Senescence; Cyclin-Dependent Kinase Inhibitor p16; Disease Models, Animal; Disease Susceptibility; Epithelial Cells; Gene Expression; Humans; Liver Cirrhosis, Biliary; Mice; Ursodeoxycholic Acid | 2020 |
Ursodeoxycholic acid alleviates experimental liver fibrosis involving inhibition of autophagy.
Topics: Animals; Autophagy; Blotting, Western; Cell Line; Disease Models, Animal; Humans; Hydroxychloroquine; Hydroxyproline; Liver Cirrhosis; Male; Rats; Rats, Sprague-Dawley; Reverse Transcriptase Polymerase Chain Reaction; Transforming Growth Factor beta1; Ursodeoxycholic Acid | 2020 |
Ursodeoxycholic Acid Attenuates the Retinal Vascular Abnormalities in Anti-PDGFR-β Antibody-Induced Pericyte Depletion Mouse Models.
Topics: Animals; Chemokine CCL2; Diabetic Retinopathy; Disease Models, Animal; Intercellular Adhesion Molecule-1; Mice; Pericytes; Receptor, Platelet-Derived Growth Factor beta; Retinal Vessels; Ursodeoxycholic Acid; Vascular Endothelial Growth Factor A | 2020 |
Synthetic Conjugates of Ursodeoxycholic Acid Inhibit Cystogenesis in Experimental Models of Polycystic Liver Disease.
Topics: Animals; Apoptosis; Bile Acids and Salts; Bile Ducts; Cell Proliferation; Cysts; Disease Models, Animal; Histone Deacetylase 6; Liver; Liver Diseases; Random Allocation; Rats; Synthetic Drugs; Ursodeoxycholic Acid | 2021 |
Ursodeoxycholic acid inhibits intimal hyperplasia, vascular smooth muscle cell excessive proliferation, migration via blocking miR-21/PTEN/AKT/mTOR signaling pathway.
Topics: Animals; Antagomirs; Cell Movement; Cell Proliferation; Cells, Cultured; Disease Models, Animal; Hyperplasia; Male; MicroRNAs; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Rats; Rats, Sprague-Dawley; Signal Transduction; TOR Serine-Threonine Kinases; Transfection; Tunica Intima; Ursodeoxycholic Acid; Vascular System Injuries | 2020 |
A dysregulated bile acid-gut microbiota axis contributes to obesity susceptibility.
Topics: Adipose Tissue, Brown; Animals; Body Mass Index; Chenodeoxycholic Acid; Cholestenones; Clostridiales; Cohort Studies; Diet, High-Fat; Disease Models, Animal; Disease Susceptibility; Gastrointestinal Microbiome; Gene Expression Regulation; Glucagon-Like Peptide 1; Humans; Ileum; Lithocholic Acid; Male; Metagenomics; Mice; Mice, Inbred C57BL; Obesity; Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha; Uncoupling Protein 1; Ursodeoxycholic Acid | 2020 |
The secondary bile acids, ursodeoxycholic acid and lithocholic acid, protect against intestinal inflammation by inhibition of epithelial apoptosis.
Topics: Animals; Apoptosis; Cholagogues and Choleretics; Detergents; Disease Models, Animal; Inflammatory Bowel Diseases; Intestinal Mucosa; Lithocholic Acid; Male; Mice; Mice, Inbred C57BL; Permeability; Protective Agents; Ursodeoxycholic Acid | 2020 |
Pharmacological Effects of Secondary Bile Acid Microparticles in Diabetic Murine Model.
Topics: Animals; Bile Acids and Salts; Diabetes Mellitus, Type 2; Disease Models, Animal; Humans; Mice; Mice, Inbred BALB C; Ursodeoxycholic Acid | 2022 |
The effect of ursodeoxycholic acid on the relative expression of the lipid metabolism genes in mouse cholesterol gallstone models.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily G, Member 8; Bile; Bile Acids and Salts; Cholestanetriol 26-Monooxygenase; Cholesterol 7-alpha-Hydroxylase; Diet; Disease Models, Animal; Gallstones; Gene Expression Regulation; Lipid Metabolism; Lipoproteins; Liver; Male; Mice, Inbred C57BL; PPAR alpha; Ursodeoxycholic Acid | 2020 |
Neuroprotective activity of ursodeoxycholic acid in CHMP2B
Topics: Animals; Apoptosis; Cell Survival; Dendrites; Disease Models, Animal; Drosophila; Drosophila Proteins; Endosomal Sorting Complexes Required for Transport; Endosomes; Frontotemporal Dementia; Glutathione; Lysosomes; Neurons; Neuroprotective Agents; Presynaptic Terminals; Primary Cell Culture; Rats; Synapses; Ubiquitinated Proteins; Ursodeoxycholic Acid; Vesicular Transport Proteins | 2020 |
Ursodeoxycholic acid protects neonatal rats from necrotizing enterocolitis: a biochemical, histopathological, and immunohistochemical study.
Topics: Animals; Animals, Newborn; Anti-Inflammatory Agents; Antioxidants; Disease Models, Animal; Enterocolitis, Necrotizing; Rats; Ursodeoxycholic Acid | 2021 |
Ursodesoxycholic acid alleviates liver fibrosis via proregeneration by activation of the ID1-WNT2/HGF signaling pathway.
Topics: Animals; Disease Models, Animal; Hepatocyte Growth Factor; Inhibitor of Differentiation Protein 1; Liver Cirrhosis; Liver Regeneration; Male; Mice; Mice, Inbred C57BL; Signal Transduction; Ursodeoxycholic Acid; Wnt Proteins | 2021 |
Glycoursodeoxycholic Acid Ameliorates Atherosclerosis and Alters Gut Microbiota in Apolipoprotein E-Deficient Mice.
Topics: Animals; Apolipoproteins E; Atherosclerosis; Cells, Cultured; Disease Models, Animal; Disease Progression; Down-Regulation; Female; Foam Cells; Gastrointestinal Microbiome; Gene Expression Regulation; Humans; Immunohistochemistry; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; RNA, Messenger; Scavenger Receptors, Class A; Ursodeoxycholic Acid | 2021 |
24-Norursodeoxycholic acid reshapes immunometabolism in CD8
Topics: Animals; CD8-Positive T-Lymphocytes; Disease Models, Animal; Inflammation; Liver; Mice; Mice, Inbred C57BL; Ursodeoxycholic Acid | 2021 |
Doxycycline-tauroursodeoxycholic acid treatment: effects in the heart of a transthyretin V30M transgenic mouse model.
Topics: Amyloid; Amyloid Neuropathies, Familial; Animals; Biomarkers; Cardiomyopathies; Collagen Type IV; Disease Models, Animal; Doxycycline; Drug Administration Schedule; Drug Therapy, Combination; Gene Expression; Heart; Heat Shock Transcription Factors; Humans; Male; Mice; Mice, Transgenic; Mutation; Natriuretic Peptide, Brain; Peptide Fragments; Prealbumin; Ursodeoxycholic Acid | 2017 |
Protective effects of ursodeoxycholic acid in experimental corrosive esophagitis injury in rats.
Topics: Animals; Burns, Chemical; Caustics; Disease Models, Animal; Esophageal Stenosis; Esophagitis; Protective Agents; Random Allocation; Rats; Rats, Wistar; Treatment Outcome; Ursodeoxycholic Acid | 2017 |
Ursodeoxycholic acid attenuates experimental autoimmune arthritis by targeting Th17 and inducing pAMPK and transcriptional corepressor SMILE.
Topics: AMP-Activated Protein Kinases; Animals; Arthritis, Experimental; Autoimmune Diseases; Basic-Leucine Zipper Transcription Factors; Biomarkers; Cytokines; Disease Models, Animal; Humans; Lipid Metabolism; Lipids; Male; Mice; Th17 Cells; Ursodeoxycholic Acid | 2017 |
Treatment with milk thistle extract (Silybum marianum), ursodeoxycholic acid, or their combination attenuates cholestatic liver injury in rats: Role of the hepatic stem cells.
Topics: Alanine Transaminase; Animals; Aspartate Aminotransferases; Cholagogues and Choleretics; Cholestasis; Disease Models, Animal; Drug Therapy, Combination; Female; Hepatocytes; Liver; Liver Cirrhosis; Malondialdehyde; Peroxidase; Phytotherapy; Plant Extracts; Rats; Rats, Sprague-Dawley; Silybum marianum; Stem Cells; Ursodeoxycholic Acid | 2017 |
Ursodeoxycholic acid protects against intestinal barrier breakdown by promoting enterocyte migration via EGFR- and COX-2-dependent mechanisms.
Topics: Animals; Bile Acids and Salts; Cell Movement; Cholagogues and Choleretics; Cyclooxygenase 2; Disease Models, Animal; Enterocytes; ErbB Receptors; Intestinal Diseases; Mice; Protective Factors; Sepsis; Ursodeoxycholic Acid | 2018 |
High Dose and Delayed Treatment with Bile Acids Ineffective in RML Prion-Infected Mice.
Topics: Animals; Anti-Infective Agents; Disease Models, Animal; Drug Administration Schedule; Female; Male; Mice; Prion Diseases; PrPSc Proteins; Survival Analysis; Taurochenodeoxycholic Acid; Time-to-Treatment; Treatment Failure; Ursodeoxycholic Acid | 2018 |
Ursodeoxycholic acid suppresses the formation of fructose/streptozotocin-induced diabetic cataract in rats.
Topics: Animals; Antioxidants; Cataract; Diabetes Mellitus, Experimental; Disease Models, Animal; Fructose; Glutathione; Hyperglycemia; Insulin; Lens, Crystalline; Male; Malondialdehyde; Oxidative Stress; Rats; Rats, Wistar; Streptozocin; Ursodeoxycholic Acid | 2018 |
Metformin treatment prevents gallstone formation but mimics porcelain gallbladder in C57Bl/6 mice.
Topics: Animals; Calcinosis; Cholagogues and Choleretics; Cholesterol; Diabetes Mellitus, Type 2; Diet, High-Fat; Disease Models, Animal; Gallbladder; Gallbladder Diseases; Gallstones; Humans; Hypoglycemic Agents; Male; Metabolic Syndrome; Metformin; Mice; Mice, Inbred C57BL; Ursodeoxycholic Acid | 2018 |
NorUDCA promotes degradation of α1-antitrypsin mutant Z protein by inducing autophagy through AMPK/ULK1 pathway.
Topics: Adenylate Kinase; alpha 1-Antitrypsin; Animals; Autophagy; Autophagy-Related Protein-1 Homolog; Disease Models, Animal; HeLa Cells; Humans; Intracellular Signaling Peptides and Proteins; Liver; Liver Diseases; Mice; Mutant Proteins; Proteolysis; RNA, Messenger; Signal Transduction; TOR Serine-Threonine Kinases; Ursodeoxycholic Acid | 2018 |
Vitamin A can ameliorate fibrosis of liver in an established rat model of biliary atresia and Kasai portoenterostomy.
Topics: Animals; Biliary Atresia; Biomarkers; Cholagogues and Choleretics; Disease Models, Animal; Glucocorticoids; Immunohistochemistry; Liver; Liver Cirrhosis; Portoenterostomy, Hepatic; Prednisolone; Rats; Rats, Sprague-Dawley; Treatment Outcome; Ursodeoxycholic Acid; Vitamin A | 2018 |
Therapeutic effects of curcumin and ursodexycholic acid on non-alcoholic fatty liver disease.
Topics: Animals; Antioxidants; Biomarkers; Curcumin; Diet, High-Fat; Disease Models, Animal; Drug Therapy, Combination; Liver; Male; Non-alcoholic Fatty Liver Disease; Rats, Wistar; Ursodeoxycholic Acid | 2019 |
Anticholestatic mechanisms of ursodeoxycholic acid in lipopolysaccharide-induced cholestasis.
Topics: Alkaline Phosphatase; Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cholagogues and Choleretics; Cholestasis; Disease Models, Animal; Hepatocytes; Lipopolysaccharides; Liver; Male; Rats; Rats, Wistar; Treatment Outcome; Ursodeoxycholic Acid | 2019 |
Anti-inflammatory and anti-oxidative effects of corilagin in a rat model of acute cholestasis.
Topics: Acute Disease; Alanine Transaminase; Analysis of Variance; Animals; Anti-Inflammatory Agents; Aspartate Aminotransferases; Bilirubin; Cholagogues and Choleretics; Cholestasis; Dexamethasone; Disease Models, Animal; Glucosides; Hydrolyzable Tannins; Liver; Male; Malondialdehyde; NF-kappa B; Nitric Oxide; Oxidative Stress; Peroxidase; Rats; Rats, Sprague-Dawley; Superoxide Dismutase; Ursodeoxycholic Acid | 2013 |
Defective canalicular transport and toxicity of dietary ursodeoxycholic acid in the abcb11-/- mouse: transport and gene expression studies.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Sub-Family B Member 4; ATP-Binding Cassette Transporters; Bile Canaliculi; Biological Transport; Cholestasis; Diet; Disease Models, Animal; Gene Expression Regulation; Infusions, Intravenous; Liver; Mice; Mice, Knockout; Multidrug Resistance-Associated Proteins; RNA, Messenger; Taurochenodeoxycholic Acid; Time Factors; Ursodeoxycholic Acid | 2013 |
Bile acids trigger cholemic nephropathy in common bile-duct-ligated mice.
Topics: Animals; Bile Acids and Salts; Cholestasis; Common Bile Duct; Disease Models, Animal; Kidney Diseases; Kidney Tubules; Ligation; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Nephritis, Interstitial; Receptors, Cytoplasmic and Nuclear; Ursodeoxycholic Acid | 2013 |
All-trans-retinoic acid improves cholestasis in α-naphthylisothiocyanate-treated rats and Mdr2-/- mice.
Topics: 1-Naphthylisothiocyanate; Animals; ATP Binding Cassette Transporter, Subfamily B; ATP-Binding Cassette Sub-Family B Member 4; Bile Acids and Salts; Cell Proliferation; Cholagogues and Choleretics; Cholestasis; Chronic Disease; Disease Models, Animal; Drug Therapy, Combination; Liver; Male; Mice; Mice, Knockout; Rats; Rats, Sprague-Dawley; Tretinoin; Ursodeoxycholic Acid | 2014 |
Glycoursodeoxycholic acid reduces matrix metalloproteinase-9 and caspase-9 activation in a cellular model of superoxide dismutase-1 neurodegeneration.
Topics: Amyotrophic Lateral Sclerosis; Animals; Caspase 9; Disease Models, Animal; Matrix Metalloproteinase 9; Mice; Motor Neurons; Mutation; Spinal Cord; Superoxide Dismutase; Superoxide Dismutase-1; Ursodeoxycholic Acid | 2015 |
Chemoprevention of esophageal adenocarcinoma in a rat model by ursodeoxycholic acid.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; CDX2 Transcription Factor; Chemoprevention; Disease Models, Animal; Esophageal Neoplasms; Esophagus; Gene Expression Profiling; Histocytochemistry; Homeodomain Proteins; Immunohistochemistry; Male; Microscopy; NF-kappa B; Rats, Wistar; Transcription Factors; Treatment Outcome; Ursodeoxycholic Acid | 2015 |
24-nor-ursodeoxycholic acid ameliorates inflammatory response and liver fibrosis in a murine model of hepatic schistosomiasis.
Topics: Animals; Cholagogues and Choleretics; Disease Models, Animal; Drug Monitoring; Granuloma; Immunohistochemistry; Inflammation; Liver Cirrhosis; Lymphocyte Activation; Mice; Schistosomiasis mansoni; T-Lymphocytes; Treatment Outcome; Ursodeoxycholic Acid | 2015 |
U12, a UDCA derivative, acts as an anti-hepatoma drug lead and inhibits the mTOR/S6K1 and cyclin/CDK complex pathways.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Cycle Checkpoints; Cell Line, Tumor; Cyclin-Dependent Kinases; Cyclins; Disease Models, Animal; Humans; Liver Neoplasms; Male; Mice; Protein Binding; Ribosomal Protein S6 Kinases, 70-kDa; Signal Transduction; TOR Serine-Threonine Kinases; Tumor Burden; Ursodeoxycholic Acid; Xenograft Model Antitumor Assays | 2014 |
Ursodeoxycholic Acid Ameliorates Apoptotic Cascade in the Rotenone Model of Parkinson's Disease: Modulation of Mitochondrial Perturbations.
Topics: Adenosine Triphosphate; Animals; Apoptosis; Behavior, Animal; Caspases; Disease Models, Animal; Dopamine; Gene Expression Regulation; Male; Mitochondria; Neostriatum; Neurons; Parkinson Disease; Rats, Wistar; RNA, Messenger; Rotenone; Ursodeoxycholic Acid | 2016 |
Ursodeoxycholic acid inhibits hepatic cystogenesis in experimental models of polycystic liver disease.
Topics: Animals; Apoptosis; Bile Acids and Salts; Bile Ducts; Calcium; Cell Proliferation; Cells, Cultured; Cholagogues and Choleretics; Cysts; Disease Models, Animal; Liver; Liver Diseases; Rats; Tandem Mass Spectrometry; Ursodeoxycholic Acid | 2015 |
Ursodeoxycholyl Lysophosphatidylethanolamide modifies aberrant lipid profiles in NAFLD.
Topics: Aldehyde Oxidase; Animals; Arachidonic Acid; Carnitine O-Palmitoyltransferase; Cholagogues and Choleretics; Diet, High-Fat; Disease Models, Animal; Docosahexaenoic Acids; Eicosapentaenoic Acid; Fatty Acids; Lipid Metabolism; Liver; Lysophospholipids; Mass Spectrometry; Mice; Mitochondria; Non-alcoholic Fatty Liver Disease; Oxidation-Reduction; Phosphatidylcholines; PPAR alpha; Real-Time Polymerase Chain Reaction; RNA, Messenger; Transcriptome; Ursodeoxycholic Acid | 2015 |
Protective effect of ursodeoxycholic acid, resveratrol, and N-acetylcysteine on nonalcoholic fatty liver disease in rats.
Topics: Acetylcysteine; Animals; Antioxidants; Biomarkers; Choline Deficiency; Cytoprotection; Disease Models, Animal; Hypolipidemic Agents; Lipids; Liver; Male; Methionine; Non-alcoholic Fatty Liver Disease; Oxidative Stress; Rats, Wistar; Resveratrol; Stilbenes; Ursodeoxycholic Acid | 2016 |
In vivo treatment with the NF-κB inhibitor ursodeoxycholic acid (UDCA) improves tension development in the isolated mdx costal diaphragm.
Topics: Animals; Biophysics; Diaphragm; Disease Models, Animal; Electric Stimulation; Enzyme Inhibitors; Mice; Mice, Inbred C57BL; Mice, Inbred mdx; Muscle Contraction; Muscular Dystrophies; Ursodeoxycholic Acid | 2016 |
Ursodeoxycholic Acid (UDCA) Exerts Anti-Atherogenic Effects by Inhibiting Endoplasmic Reticulum (ER) Stress Induced by Disturbed Flow.
Topics: Animals; Apoptosis; Atherosclerosis; Blood Circulation; Carotid Artery, Common; Cell Adhesion; Cell Adhesion Molecules; Cells, Cultured; Disease Models, Animal; DNA-Binding Proteins; Down-Regulation; Endoplasmic Reticulum; Endoplasmic Reticulum Stress; Human Umbilical Vein Endothelial Cells; Humans; Inflammation; Male; Mice; Monocytes; Plaque, Atherosclerotic; Regulatory Factor X Transcription Factors; Stress, Mechanical; Transcription Factor CHOP; Transcription Factors; Ursodeoxycholic Acid; X-Box Binding Protein 1 | 2015 |
Histopathologic and metabolic effect of ursodeoxycholic acid treatment on PCOS rat model.
Topics: Animals; Cholagogues and Choleretics; Disease Models, Animal; Female; Ovary; Polycystic Ovary Syndrome; Rats; Rats, Wistar; Ursodeoxycholic Acid | 2016 |
Influence of 24-Nor-Ursodeoxycholic Acid on Hepatic Disposition of [(18)F]Ciprofloxacin, a Positron Emission Tomography Study in Mice.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP-Binding Cassette Sub-Family B Member 4; Biological Transport; CHO Cells; Cholestasis; Ciprofloxacin; Cricetulus; Disease Models, Animal; Female; Fluorine Radioisotopes; Liver; Mice, Knockout; Multidrug Resistance-Associated Proteins; Organ Specificity; Positron-Emission Tomography; Substrate Specificity; Tissue Distribution; Ursodeoxycholic Acid | 2016 |
Ursodeoxycholic Acid Attenuates Acute Aortic Dissection Formation in Angiotensin II-Infused Apolipoprotein E-Deficient Mice Associated with Reduced ROS and Increased Nrf2 Levels.
Topics: Angiotensin II; Animals; Aorta, Abdominal; Aortic Aneurysm, Abdominal; Apolipoproteins E; Apoptosis; bcl-2-Associated X Protein; Cells, Cultured; Cholagogues and Choleretics; Disease Models, Animal; Down-Regulation; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Muscle, Smooth, Vascular; NF-E2-Related Factor 2; Oxidative Stress; Proto-Oncogene Proteins c-bcl-2; Reactive Oxygen Species; Up-Regulation; Ursodeoxycholic Acid | 2016 |
Autophagy induced by exogenous bile acids is therapeutic in a model of α-1-AT deficiency liver disease.
Topics: alpha 1-Antitrypsin; alpha 1-Antitrypsin Deficiency; Animals; Autophagy; Cells, Cultured; Deoxycholic Acid; Disease Models, Animal; Genetic Predisposition to Disease; Humans; Liver; Liver Cirrhosis; Mice, Inbred C57BL; Mice, Transgenic; Mutation; Phenotype; Transfection; Ursodeoxycholic Acid | 2016 |
Long-Term Supplementation of Microencapsulated ursodeoxycholic Acid Prevents Hypertension in a Mouse Model of Insulin Resistance.
Topics: Angiotensin II; Animals; Capsules; Diabetes Complications; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dietary Supplements; Disease Models, Animal; Hypertension; Insulin Resistance; Male; Mice; Time Factors; Ursodeoxycholic Acid | 2017 |
Ursodeoxycholic Acid and Its Taurine- or Glycine-Conjugated Species Reduce Colitogenic Dysbiosis and Equally Suppress Experimental Colitis in Mice.
Topics: Animals; Bacteroides; Colon; Dextran Sulfate; Disease Models, Animal; Dysbiosis; Feces; Firmicutes; Gastrointestinal Microbiome; Humans; Inflammatory Bowel Diseases; Mice; Taurine; Taurochenodeoxycholic Acid; Ursodeoxycholic Acid | 2017 |
NorUrsodeoxycholic acid ameliorates cholemic nephropathy in bile duct ligated mice.
Topics: Animals; Bile Acids and Salts; Cholestasis; Disease Models, Animal; Fibrosis; Kidney; Kidney Diseases; Ligation; Lipocalin-2; Male; Mice; Mice, Inbred C57BL; Nephritis, Interstitial; Ursodeoxycholic Acid | 2017 |
Effective treatment of unconjugated hyperbilirubinemia with oral bile salts in Gunn rats.
Topics: Administration, Oral; Animals; Bile Acids and Salts; Bilirubin; Cholic Acid; Disease Models, Animal; Dose-Response Relationship, Drug; Feces; Gastrointestinal Agents; Hyperbilirubinemia; Male; Rats; Tritium; Ursodeoxycholic Acid | 2009 |
Treatment with inhibitors of the NF-kappaB pathway improves whole body tension development in the mdx mouse.
Topics: Animals; Antioxidants; Cholagogues and Choleretics; Disease Models, Animal; Female; Male; Mice; Mice, Inbred mdx; Muscle Strength; Muscle Stretching Exercises; Muscle Tonus; Muscle Weakness; Muscle, Skeletal; Muscular Dystrophy, Duchenne; NF-kappa B; Pyrrolidines; Recovery of Function; Thiocarbamates; Transcription Factor RelA; Treatment Outcome; Ursodeoxycholic Acid | 2009 |
Learning from the pregnane X receptor: how to fight one aggressor with two strategies.
Topics: Animals; Apoptosis; Cholagogues and Choleretics; Cholangitis, Sclerosing; Cholestasis, Intrahepatic; Disease Models, Animal; Glycochenodeoxycholic Acid; Hepatocytes; Humans; Liver Cirrhosis, Biliary; Pregnane X Receptor; Rats; Receptors, Steroid; Ursodeoxycholic Acid | 2010 |
Ursodeoxycholic acid and tauroursodeoxycholic acid suppress choroidal neovascularization in a laser-treated rat model.
Topics: Animals; Anti-Inflammatory Agents; Argon; Choroidal Neovascularization; Disease Models, Animal; Enzyme-Linked Immunosorbent Assay; Laser Coagulation; Male; Rats; Rats, Inbred BN; Taurochenodeoxycholic Acid; Ursodeoxycholic Acid; Vascular Endothelial Growth Factor A | 2010 |
Combinatorial chemoprevention reveals a novel smoothened-independent role of GLI1 in esophageal carcinogenesis.
Topics: Adenocarcinoma; Animals; Anticarcinogenic Agents; Aspirin; Barrett Esophagus; Cell Growth Processes; Cyclin-Dependent Kinase 2; Disease Models, Animal; Down-Regulation; Esophageal Neoplasms; Humans; Oncogene Proteins; Promoter Regions, Genetic; Protein Binding; Rats; Trans-Activators; Transfection; Ursodeoxycholic Acid; Zinc Finger Protein GLI1 | 2010 |
The correlation between NF-κB inhibition and disease activity by coadministration of silibinin and ursodeoxycholic acid in experimental colitis.
Topics: Animals; Antioxidants; Cholagogues and Choleretics; Colitis; Dexamethasone; Disease Models, Animal; Drug Therapy, Combination; Male; NF-kappa B; Rats; Rats, Wistar; Silybin; Silymarin; Trinitrobenzenesulfonic Acid; Ursodeoxycholic Acid | 2011 |
Ursodeoxycholic acid promotes intestinal adaptation in a cat model of short bowel syndrome.
Topics: Adaptation, Physiological; Animals; Cats; Cholagogues and Choleretics; Diarrhea; Disease Models, Animal; DNA; Hyperplasia; Ileum; Intestinal Mucosa; Jejunum; Short Bowel Syndrome; Sucrase; Ursodeoxycholic Acid | 2011 |
Combination of retinoic acid and ursodeoxycholic acid attenuates liver injury in bile duct-ligated rats and human hepatic cells.
Topics: Animals; Bile Acids and Salts; Bile Ducts; Cell Proliferation; Cells, Cultured; Cholestasis, Intrahepatic; Cholesterol 7-alpha-Hydroxylase; Collagen Type I; Collagen Type I, alpha 1 Chain; Disease Models, Animal; Hepatocytes; Humans; Ligation; Liver; Male; Matrix Metalloproteinase 2; Rats; Rats, Sprague-Dawley; Smad2 Protein; Tretinoin; Ursodeoxycholic Acid | 2011 |
Loss of CFTR affects biliary epithelium innate immunity and causes TLR4-NF-κB-mediated inflammatory response in mice.
Topics: Animals; Anti-Bacterial Agents; Bile Ducts; Cholagogues and Choleretics; Cholangitis; Colitis; Cytokines; Dextran Sulfate; Disease Models, Animal; Epithelial Cells; HEK293 Cells; Humans; Immunity, Innate; Inflammation Mediators; Keratin-19; Leukocyte Common Antigens; Lipopolysaccharides; Mice; Mice, Inbred C57BL; Mice, Inbred CFTR; Mice, Knockout; Neomycin; NF-kappa B; Phosphorylation; Polymyxin B; src-Family Kinases; Time Factors; Toll-Like Receptor 4; Transfection; Ursodeoxycholic Acid | 2011 |
A protective antiarrhythmic role of ursodeoxycholic acid in an in vitro rat model of the cholestatic fetal heart.
Topics: Adult; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Cells, Cultured; Cholestasis, Intrahepatic; Disease Models, Animal; Female; Fetal Heart; Heart Ventricles; Humans; In Vitro Techniques; Muscle Cells; Pregnancy; Pregnancy Complications; Rats; Rats, Wistar; Treatment Outcome; Ursodeoxycholic Acid | 2011 |
Alterations in lipid metabolism mediate inflammation, fibrosis, and proliferation in a mouse model of chronic cholestatic liver injury.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP-Binding Cassette Sub-Family B Member 4; Bile Acids and Salts; Cell Proliferation; Cholestasis, Intrahepatic; Chronic Disease; Dietary Fats; Disease Models, Animal; Disease Progression; Fatty Acids; Female; Fenofibrate; Gene Expression Profiling; Gene Expression Regulation; Hepatitis; Hypolipidemic Agents; Lipid Metabolism; Liver; Liver Cirrhosis; Metabolomics; Mice; Mice, Knockout; Oligonucleotide Array Sequence Analysis; PPAR gamma; Pregnancy; Prenatal Exposure Delayed Effects; Triglycerides; Ursodeoxycholic Acid | 2012 |
Ursodeoxycholyl lysophosphatidylethanolamide improves steatosis and inflammation in murine models of nonalcoholic fatty liver disease.
Topics: Animals; Biopsy, Needle; Caspase 8; Diet; Disease Models, Animal; Down-Regulation; Fatty Liver; Hepatitis; Immunohistochemistry; Lipid Peroxidation; Lipogenesis; Liver Function Tests; Male; Mice; Mice, Inbred C57BL; Non-alcoholic Fatty Liver Disease; Random Allocation; Real-Time Polymerase Chain Reaction; Sensitivity and Specificity; Transaminases; Triglycerides; Ursodeoxycholic Acid | 2012 |
The effect of ursodeoxycholic acid on oxidative stress level and DNase activity in rat liver after bile duct ligation.
Topics: Animals; Apoptosis; Catalase; Cholagogues and Choleretics; Cholestasis, Extrahepatic; Common Bile Duct; Deoxyribonuclease I; Disease Models, Animal; Endodeoxyribonucleases; Lipid Peroxidation; Liver; Malondialdehyde; Oxidative Stress; Rats; Rats, Wistar; Reactive Oxygen Species; Ursodeoxycholic Acid; Xanthine Oxidase | 2013 |
Specific bile acids inhibit hepatic fatty acid uptake in mice.
Topics: Animals; Bile Acids and Salts; Cells, Cultured; Deoxycholic Acid; Disease Models, Animal; Fatty Acid Transport Proteins; Fatty Acids; Hepatocytes; Humans; Injections, Subcutaneous; Lipid Metabolism; Lithocholic Acid; Mice; Mice, Inbred Strains; Random Allocation; Real-Time Polymerase Chain Reaction; Sensitivity and Specificity; Ursodeoxycholic Acid | 2012 |
Hepatocyte transplantation in bile salt export pump-deficient mice: selective growth advantage of donor hepatocytes under bile acid stress.
Topics: Animals; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Transplantation; Cholestasis, Intrahepatic; Cholic Acid; Disease Models, Animal; Hepatocytes; Liver; Liver Regeneration; Mice; Mice, Mutant Strains; Transplants; Ursodeoxycholic Acid | 2012 |
Ursodeoxycholic acid suppresses eosinophilic airway inflammation by inhibiting the function of dendritic cells through the nuclear farnesoid X receptor.
Topics: Animals; Asthma; Cell Communication; Cell Survival; Cytokines; Dendritic Cells; Disease Models, Animal; Eosinophils; Female; Immunologic Factors; Inflammation; Mice; Mice, Knockout; Pulmonary Eosinophilia; Receptors, Cytoplasmic and Nuclear; T-Lymphocytes; Th1 Cells; Ursodeoxycholic Acid | 2012 |
Dose-dependent antiinflammatory effect of ursodeoxycholic acid in experimental colitis.
Topics: Administration, Oral; Alkaline Phosphatase; Animals; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Crohn Disease; Disease Models, Animal; Dose-Response Relationship, Drug; Female; Humans; Intestinal Mucosa; Rats; Rats, Wistar; Trinitrobenzenesulfonic Acid; Ursodeoxycholic Acid | 2013 |
Artemisia capillaris extract protects against bile duct ligation-induced liver fibrosis in rats.
Topics: Animals; Antioxidants; Artemisia; Cholagogues and Choleretics; Cholestasis; Disease Models, Animal; Dose-Response Relationship, Drug; Drugs, Chinese Herbal; Liver Cirrhosis; Liver Function Tests; Male; Rats; Rats, Sprague-Dawley; Ursodeoxycholic Acid | 2013 |
Ursodeoxycholic acid aggravates bile infarcts in bile duct-ligated and Mdr2 knockout mice via disruption of cholangioles.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP-Binding Cassette Transporters; Bile; Bile Acids and Salts; Cholagogues and Choleretics; Cholangitis, Sclerosing; Cholestasis, Extrahepatic; Common Bile Duct; Disease Models, Animal; Infarction; Ligation; Male; Mice; Mice, Knockout; Necrosis; Pressure; Ursodeoxycholic Acid | 2002 |
Ursodeoxycholic acid inhibits the initiation and postinitiation phases of azoxymethane-induced colonic tumor development.
Topics: Animals; Azoxymethane; Cholagogues and Choleretics; Colonic Neoplasms; Disease Models, Animal; Disease Progression; Dose-Response Relationship, Drug; Incidence; Male; Rats; Rats, Inbred F344; Time Factors; Treatment Outcome; Ursodeoxycholic Acid | 2002 |
Ursodeoxycholic acid and F(6)-D(3) inhibit aberrant crypt proliferation in the rat azoxymethane model of colon cancer: roles of cyclin D1 and E-cadherin.
Topics: Animals; Azoxymethane; Base Sequence; Biomarkers, Tumor; Biopsy, Needle; Blotting, Western; Cadherins; Cell Division; Cholecalciferol; Colonic Neoplasms; Cyclin D1; Disease Models, Animal; Immunohistochemistry; Injections, Intraperitoneal; Intestinal Mucosa; Male; Molecular Sequence Data; Neoplasms, Experimental; Polymerase Chain Reaction; Random Allocation; Rats; Rats, Inbred F344; Reference Values; RNA, Messenger; Sensitivity and Specificity; Ursodeoxycholic Acid | 2002 |
Usefulness of liposomes loaded with cytostatic bile acid derivatives to circumvent chemotherapy resistance of enterohepatic tumors.
Topics: Animals; Antineoplastic Agents; Bile Acids and Salts; Cisplatin; Disease Models, Animal; Drug Carriers; Drug Delivery Systems; Drug Resistance, Neoplasm; Humans; Liposomes; Mice; Mice, Nude; Neoplasm Transplantation; Neoplasms, Experimental; Organoplatinum Compounds; Treatment Outcome; Tumor Cells, Cultured; Ursodeoxycholic Acid | 2003 |
Ursodeoxycholate further increases bile-duct cell proliferative response induced by partial bile-duct ligation in rats.
Topics: Administration, Oral; Animals; Bile Ducts; Cell Division; Cholagogues and Choleretics; Cholestasis, Extrahepatic; Cholestasis, Intrahepatic; Deoxycholic Acid; Diet; Disease Models, Animal; Ligation; Liver; Liver Function Tests; Proliferating Cell Nuclear Antigen; Rats; Rats, Inbred F344; Ursodeoxycholic Acid | 2004 |
Ursodeoxycholic acid ameliorates experimental ileitis counteracting intestinal barrier dysfunction and oxidative stress.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Disease Models, Animal; Ileitis; Indomethacin; Intestinal Mucosa; Male; Oxidative Stress; Random Allocation; Rats; Rats, Wistar; Reactive Oxygen Species; Ursodeoxycholic Acid | 2004 |
Oxidative stress and apoptosis in fetal rat liver induced by maternal cholestasis. Protective effect of ursodeoxycholic acid.
Topics: Adaptor Proteins, Signal Transducing; Animals; Apoptosis; bcl-2-Associated X Protein; Bile Acids and Salts; Biomarkers; Caspase 3; Caspases; Cholagogues and Choleretics; Cholestasis; Disease Models, Animal; Enzyme Precursors; Female; Liver; Maternal-Fetal Exchange; Oxidative Stress; Pregnancy; Proto-Oncogene Proteins c-bcl-2; Rats; Rats, Wistar; Ursodeoxycholic Acid | 2005 |
Prevention of colitis-associated carcinogenesis in a mouse model by diet supplementation with ursodeoxycholic acid.
Topics: Administration, Oral; Animals; Bile Acids and Salts; Carcinoma; Cell Transformation, Neoplastic; Cholagogues and Choleretics; Colitis; Colon; Colorectal Neoplasms; Diet; Disease Models, Animal; Female; Mice; Mice, Inbred C57BL; Ursodeoxycholic Acid | 2006 |
Ca2+-dependent cytoprotective effects of ursodeoxycholic and tauroursodeoxycholic acid on the biliary epithelium in a rat model of cholestasis and loss of bile ducts.
Topics: Animals; Apoptosis; Bile Ducts; Calcium; Cell Proliferation; Cholestasis; Cytoprotection; Disease Models, Animal; Egtazic Acid; Enzyme Activation; Epithelium; Ligation; Male; Mitogen-Activated Protein Kinase Kinases; Phosphatidylinositol 3-Kinases; Phosphorylation; Protein Kinase C-alpha; Rats; Rats, Inbred F344; Signal Transduction; Taurochenodeoxycholic Acid; Ursodeoxycholic Acid; Vagotomy | 2006 |
24-norUrsodeoxycholic acid is superior to ursodeoxycholic acid in the treatment of sclerosing cholangitis in Mdr2 (Abcb4) knockout mice.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP-Binding Cassette Sub-Family B Member 4; Bile Acids and Salts; Cholangitis, Sclerosing; Disease Models, Animal; Mice; Mice, Knockout; Ursodeoxycholic Acid | 2006 |
Ursodesoxycholic acid and heme-arginate are unable to improve hematopoiesis and liver injury in an erythropoietic protoporphyria mouse model.
Topics: Animals; Arginine; Cholagogues and Choleretics; Disease Models, Animal; Hematopoiesis; Heme; Injections, Intraperitoneal; Liver; Mice; Mice, Transgenic; Protoporphyria, Erythropoietic; Ursodeoxycholic Acid | 2006 |
Antioxidant mechanism of hepatoprotection by ursodeoxycholic acid in experimental alcoholic steatohepatitis.
Topics: Animals; Antioxidants; Aspartate Aminotransferases; Cholagogues and Choleretics; Dietary Fats; Disease Models, Animal; Ethanol; Fatty Acids; Fatty Liver, Alcoholic; gamma-Glutamyltransferase; Glutathione; Lipid Peroxidation; Liver; Male; Microsomes, Liver; Rats; Rats, Wistar; Superoxide Dismutase; Triglycerides; Ursodeoxycholic Acid | 2006 |
Ursodeoxycholic acid versus sulfasalazine in colitis-related colon carcinogenesis in mice.
Topics: Animals; Anticarcinogenic Agents; Azoxymethane; Colitis; Colonic Neoplasms; Cyclooxygenase 2; Disease Models, Animal; Male; Mice; Mice, Inbred ICR; RNA, Messenger; Sulfasalazine; Ursodeoxycholic Acid | 2007 |
[Effect of ursodeoxycholic acid in an experimental colon cancer model].
Topics: Animals; Cholagogues and Choleretics; Colonic Neoplasms; Disease Models, Animal; Female; Male; Rats; Rats, Sprague-Dawley; Ursodeoxycholic Acid | 2007 |
Therapy for nonalcoholic fatty liver disease.
Topics: Animals; Antioxidants; Cholagogues and Choleretics; Disease Models, Animal; Fatty Liver; Glycine; Humans; Hypolipidemic Agents; Insulin Resistance; Liver; Mice; Oxazoles; Peroxisome Proliferator-Activated Receptors; Rats; Thiazolidinediones; Treatment Outcome; Ursodeoxycholic Acid; Vitamin E | 2008 |
Effect of ursodeoxycholic acid on in vivo and in vitro toxic liver injury in rats.
Topics: Acetaminophen; Administration, Oral; Animals; Aspartate Aminotransferases; Carbon Tetrachloride; Carbon Tetrachloride Poisoning; Chemical and Drug Induced Liver Injury; Disease Models, Animal; Ethanol; Lipid Peroxides; Liver; Liver Diseases; Male; Rats; Ursodeoxycholic Acid; Valine | 1994 |
Ursodeoxycholic acid modifies gut-derived endotoxemia in neonatal rats.
Topics: Animals; Animals, Newborn; Biological Transport, Active; Disease Models, Animal; Endotoxins; Female; Intestinal Mucosa; Intestines; Lipopolysaccharides; Pregnancy; Rats; Rats, Sprague-Dawley; Toxemia; Tumor Necrosis Factor-alpha; Ursodeoxycholic Acid | 1994 |
Ursodeoxycholic acid ameliorates ibuprofen-induced enteropathy in the rat.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Catheterization; Cholagogues and Choleretics; Cystic Fibrosis; Disease Models, Animal; Ibuprofen; Intestinal Diseases; Intestines; Lipase; Male; Random Allocation; Rats; Rats, Sprague-Dawley; Serositis; Ulcer; Ursodeoxycholic Acid | 2001 |
Low in vivo toxicity of a novel cisplatin-ursodeoxycholic derivative (Bamet-UD2) with enhanced cytostatic activity versus liver tumors.
Topics: Animals; Antineoplastic Agents; Bone Marrow; Carcinoma, Hepatocellular; Cisplatin; Disease Models, Animal; Drug Evaluation, Preclinical; Injections, Intraperitoneal; Kidney; Kidney Function Tests; Liver; Liver Neoplasms, Experimental; Male; Mice; Mice, Nude; Myocardium; Neoplasm Transplantation; Neural Conduction; Organoplatinum Compounds; Platinum; Rats; Rats, Wistar; Sciatic Nerve; Survival Rate; Tissue Distribution; Tumor Cells, Cultured; Ursodeoxycholic Acid | 2001 |
Suppression of renal disease and mortality in the female NZB x NZW F1 mouse model of systemic lupus erythematosus (SLE) by chenodeoxycholic acid.
Topics: Albuminuria; Animals; Antibodies, Antinuclear; Blood Urea Nitrogen; Chenodeoxycholic Acid; Cholagogues and Choleretics; Cytokines; Disease Models, Animal; Female; Gastrointestinal Agents; Hemocyanins; Immunization; Immunoglobulin G; Kidney; Liver; Lupus Nephritis; Mice; Mice, Inbred NZB; Spleen; Survival Rate; Uremia; Urodynamics; Ursodeoxycholic Acid | 2001 |
Anti-inflammatory effects of 5-aminosalicylic acid conjugates with chenodeoxycholic acid and ursodeoxycholic acid on carrageenan-induced colitis in guinea-pigs.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Carrageenan; Chenodeoxycholic Acid; Colitis, Ulcerative; Disease Models, Animal; Guinea Pigs; Mesalamine; Ursodeoxycholic Acid | 2001 |
Effect of ursodeoxycholic acid on azoxymethane-induced aberrant crypt foci formation in rat colon: in vitro potential role of intracellular Ca2+.
Topics: Animals; Anticarcinogenic Agents; Azoxymethane; Bile Acids and Salts; Calcium; Calcium Signaling; Carcinogens; Colon; Colonic Neoplasms; Diet; Disease Models, Animal; Dose-Response Relationship, Drug; Intracellular Fluid; Male; Rats; Rats, Inbred F344; Tumor Cells, Cultured; Ursodeoxycholic Acid | 2002 |
[Morphological changes in rat liver in toxic drug-induced hepatitis and stimulation of repair processes].
Topics: Animals; Chemical and Drug Induced Liver Injury; Disease Models, Animal; Humans; Liver Regeneration; Rats; Ursodeoxycholic Acid | 2001 |
[Influence of ursodeoxycholic acid on the therapeutic effects of low-calorie diet in obesity and hyperlipidemia rats with steatohepatitis].
Topics: Animals; Diet; Disease Models, Animal; Food-Drug Interactions; Hepatitis; Hyperlipidemias; Obesity; Rats; Rats, Sprague-Dawley; Ursodeoxycholic Acid | 2002 |
Effect of intraduodenal administration of 23-methyl-UDCA diastereoisomers on bile flow in hamsters.
Topics: Acute Disease; Animals; Bicarbonates; Bile; Biliary Fistula; Biotransformation; Cricetinae; Disease Models, Animal; Dose-Response Relationship, Drug; Duodenum; Liver; Male; Mesocricetus; Stereoisomerism; Structure-Activity Relationship; Ursodeoxycholic Acid | 1992 |
Effects of bile acid depletion and of ursodeoxycholic and chenodeoxycholic acids on biliary protein secretion in the hamster.
Topics: Animals; Bile; Bile Acids and Salts; Biliary Fistula; Chenodeoxycholic Acid; Cholic Acid; Cholic Acids; Chromatography, Gas; Cricetinae; Deoxycholic Acid; Disease Models, Animal; Lithocholic Acid; Male; Mesocricetus; Proteins; Ursodeoxycholic Acid | 1990 |
Dissolution of cholesterol gallstones by bile acids in the prairie dog.
Topics: Animals; Bile Acids and Salts; Chenodeoxycholic Acid; Cholelithiasis; Cholesterol; Disease Models, Animal; Hydroxymethylglutaryl CoA Reductases; Male; Sciuridae; Ursodeoxycholic Acid | 1988 |